Product

Hot Products

Antibodies

Cells

Kits

Tracers

Gene Related Products

Lenti of Mouse synuclein, alpha (Snca) transcript variant (NM_001042451) ORF clone, mGFP Tagged (Cat#: NEP-0521-R0864)
Mouse Parkinson disease (autosomal recessive, early onset) 7 (Park7) (NM_020569) clone, Untagged (Cat#: NEP-0621-R0133)
Tau Antisense Oligonucleotide (IONIS-MAPTRx) (Cat#: NV-2106-P29)
Human presenilin 1 (PSEN1), transcript variant 2 (NM_007318) ORF clone, TurboGFP Tagged (Cat#: NEP-0421-R0140)
Human huntingtin-associated protein 1 (HAP1) transcript variant 2 (NM_177977) ORF clone, Myc-DDK Tagged (Cat#: NEP-0521-R0676)
Human superoxide dismutase 3, extracellular (SOD3) (NM_003102) ORF clone, Untagged (Cat#: NEP-0521-R0808)
Human superoxide dismutase 1, soluble (SOD1) (NM_000454) ORF clone, TurboGFP Tagged (Cat#: NEP-0521-R0748)
Lenti of Human TAR DNA binding protein (TARDBP) (NM_007375) ORF clone, mGFP Tagged (Cat#: NEP-0521-R0832)
Mouse SOD1 shRNA Silencing Adenovirus (Cat#: NV-2106-P14)
ABCA1 Antisense Oligonucleotide (AK311445) (Cat#: NV-2106-P27)

Biospecimens

Cell Assay Reagents

Myasthenia Gravis Related Research Tools

Myasthenia gravis (MG) is an autoimmune disease caused by antibodies against the acetylcholine receptor (AChR), muscle-specific kinase (MuSK) or other AChR-related proteins in the postsynaptic muscle membrane. Localized or general muscle weakness is the predominant symptom and is induced by the antibodies. Traditionally, most patients with MG require induction therapy with high doses of corticosteroids and maintenance with an immunosuppressant. Nowadays, biologics are emerging as important therapeutic tools that provide better corticosteroid-sparing effects than standard treatments and can even induce remission.

Fig.1 The main cells and pathways in the immune network of MG and their potential as therapeutic targets. (Dalakas, 2019)

As shown in Fig.1, immunotherapeutics that target different elements in these pathways are shown in yellow boxes. The AChR is presented to CD4+ T cells by antigen-presenting cells (APCs) via co-stimulatory molecules. Downstream upregulation of cytokines stimulates B cells to produce anti-AChR antibodies that lead to the destruction of AChRs by fixing complement at the neuromuscular endplate region. Levels of regulatory T (Treg) and T helper (TH) 17 cells and cytokines are increased in patients with MG, thereby causing the immune imbalance.

Several biologic agents have shown promising effects in studies of their efficacy in MG to date. The success suggests that the emergence of new molecular targets could bring a revolution in the treatment of MG. Creative Biolabs has screened the most popular targets and provides high-quality products as well as customized services for our clients. For more services and products, please contact us.

CD19	CD20	CD80	CD86
IL-2	IL-4	IL-6	IL-17
IL-22	JAK1	JAK2	JAK3
AchR	PD-1	PD-L1	CTLA4
C5	C3	TNF	B cell trophic factor (BAFF)

Reference

Dalakas, M. C. Immunotherapy in myasthenia gravis in the era of biologics. Nature Reviews Neurology. 2019, 15(2): 113-124.

For Research Use Only. Not For Clinical Use.

Target

NSE

NALP

ALS2CR2

POU5F1

GFAP

CLN5

Plexin A2

GEMIN8

Alpha Synuclein

NF-L

PGP9.5

NDEL1

SOD2

GAD67

BACE2

CDK2

Entactin/NID

CDK5

CASKIN

Glypican 1

NEUROG3

HIP1

ALDH3A2

ALS2CR1

STAT3 Phospho (Ser727)

Mu Opioid Receptor

GPRC5A

Polyubiquitin (K63-linkage)

Pan-KCHIP

Tenascin C

Mint-1

CDK1

Related Products

NeuroMab™ Rabbit Anti-KLK3 Monoclonal Antibody (CBP7299) [CAT#: NAB-0720-Z9964]

Prostate Specific Antigen Rabbit Monoclonal Antibody

Host Species:: Rabbit

Species Reactivity:: Mouse; Rat; Human

Applications:: WB

Conjugation:: Unconjugated; APC; PE; HRP; Biotin; FITC; Alexa Fluor 488; Alexa Fluor 700; Alexa Fluor 647; Alexa Fluor 750; Alexa Fluor 594; Alexa Fluor 350; Alexa Fluor 3560

Inquiry